Damora Q3 Loss Widens to $32.0M; $528.5M Cash Funds Runway Into 2H 2029
DMRA has more than doubled off its 52-week low of $4.95.
Summary
Damora's Q3 2026 net loss widened to $31.99M from $3.13M a year earlier on heavier R&D, while $528.5M in cash and securities funds operations into the second half of 2029. The filing also details the November 3 Paragon license for DMR-001 and DMR-002 and confirms the CLARITY-101 trial is underway.
Key Events · Earnings and Guidance · DMRA
-
Q3 Loss Widens on R&D Scale-Up
Net loss was $31.99M for Q3 2026 versus $3.13M a year earlier, and the nine-month net loss reached $90.9M versus $9.1M. R&D expense rose to $25.5M from $1.4M, including $7.2M of Paragon-related costs.
-
Cash Funds Runway Into 2H 2029
Cash, cash equivalents and marketable securities totaled $528.5M at September 30, 2026, which management says funds operations into the second half of 2029.
-
Paragon License Terms Disclosed
The November 3, 2026 Paragon License Agreement for DMR-001 and DMR-002 carries up to $22.0M in milestones per licensed product, a $2.5M first-human-dosing milestone, and low-to-mid single-digit tiered royalties.
-
CLARITY-101 Trial Progresses
The Phase 1/1b trial of DMR-001 started in Australia with FDA clearance for the U.S.; two proof-of-concept readouts are expected beginning mid-2027.
Analysis · DMRA · Life Sciences
The headline loss ballooned to $31.99M from $3.13M a year ago as R&D spending scaled up for the mutCALR antibody programs, but the balance sheet is the real story: $528.5M in cash and securities funds operations into the second half of 2029, so there is no near-term financing pressure. Hard terms also now attach to the November 3, 2026 Paragon license for DMR-001 and DMR-002 — up to $22.0M in milestones per product plus low-to-mid single-digit royalties. And the CLARITY-101 trial is running in Australia with FDA clearance for the U.S., with two proof-of-concept readouts expected beginning mid-2027.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DMRA was trading at $22.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $4.95 to $38.33. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.